Metabolon and Mayo Clinic will jointly research disease biomarkers and develop novel diagnostic tests for use in Mayo Clinic’s nationwide reference laboratories.
MORRISVILLE, N.C. – August 9, 2022 – Metabolon, Inc., the global leader in metabolomics solutions advancing a wide variety of research, diagnostic, therapeutic development, and precision medicine applications, today announced a joint development agreement with Mayo Clinic to develop novel metabolomic biomarker diagnostic tests. Metabolon will analyze Mayo Clinic patient clinical samples across multiple cohorts to look for disease biomarkers. New diagnostic tests for Mayo Clinic to use in its nationwide Mayo Clinic Laboratories will be designed using these biomarkers.
Metabolon and Mayo Clinic will initially focus their investigation on metabolite biomarkers indicating inflammatory bowel disease and non-alcoholic fatty liver disease (NAFLD). Additional potential collaboration areas include research into biomarkers revealing the presence of Alzheimer’s disease, pancreatic cancer, breast cancer, inflammatory arthritis, and others.
“We are incredibly excited to be working with Mayo Clinic, as they bring significant clinical strength and robust commercialization capabilities to this vital research. Mayo Clinic’s laboratories are the third-largest in the U.S., performing over 25 million diagnostic tests each year,» said Rohan Hastie, Ph.D., President and CEO of Metabolon. «Collaborating with Mayo Clinic has the potential to help both parties expand their cutting-edge research into the critical role of metabolomic biomarkers as valuable indicators of human health.»